MCK - McKesson Corporation
| Previous Close | 130.47 |
| Open | 130.77 |
| Bid | 130.68 x 800 |
| Ask | 130.85 x 800 |
| Day's Range | 129.22 - 131.27 |
| 52 Week Range | 117.19 - 178.86 |
| Volume | 551,106 |
| Avg. Volume | 1,542,053 |
| Market Cap | 25.502B |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (1.19%) |
| Ex-Dividend Date | 2018-11-30 |
| 1y Target Est | N/A |
Markit•5 hours agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
American City Business Journals•5 days agoWill the Bay Area quietly lose another Fortune 500 headquarters to Texas?
San Francisco quietly lost the headquarters of Core-Mark Holding Co., which disclosed on an earnings call that it's moving its headquarters to Dallas next year. Will this health care company follow?
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of MCK earnings conference call or presentation 25-Oct-18 12:00pm GMT
Q2 2019 McKesson Corp Earnings Call
- The Wall Street Journal•12 days ago
[$$] Longtime McKesson CEO to Step Down
will retire next year, capping a 17-year reign in which he helped build one of the country’s largest pharmaceutical wholesalers despite weathering shareholder criticism over his compensation and handling of the opioid crisis. , McKesson’s lead independent director, will take over as chairman of the board, the company said Thursday. “This is the right time to turn the leadership reins over to the next generation and no one is better equipped than Brian to lead McKesson into the future,” Mr. Hammergren said in a written statement.
- Morningstar•13 days ago
McKesson Is Deeply Discounted
Despite the tumult that has engulfed its operating environment, we believe McKesson MCK will remain a key healthcare player and be able to produce outsize economic value. Its fiscal second quarter reflected a stabilization of near-term issues as the company reported earnings above consensus and raised the lower end of its full-year earnings per share guidance. After factoring in these latest results, we are reiterating our $210 fair value estimate and wide economic moat rating for the pharmaceutical distributor.
- Simply Wall St.•18 days ago
Should You Worry About McKesson Corporation’s (NYSE:MCK) CEO Pay?
John Hammergren has been the CEO of McKesson Corporation (NYSE:MCK) since 2001. First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider Read More...
Motley Fool•19 days agoMcKesson Corp (MCK) Q2 2019 Earnings Conference Call Transcript
MCK earnings call for the period ending September 30, 2018.
- Motley Fool•19 days ago
International Headwinds Keep Hammering McKesson
The drug distributor's foreign exposure remains a challenge.
- Zacks•19 days ago
McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.
- Zacks•19 days ago
McKesson (MCK) Surpasses Q2 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Markit•19 days agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
- Associated Press•19 days ago
McKesson: Fiscal 2Q Earnings Snapshot
On a per-share basis, the San Francisco-based company said it had profit of $2.51. Earnings, adjusted for one-time gains and costs, were $3.60 per share. The results exceeded Wall Street expectations. ...
- Benzinga•20 days ago
McKesson's Q2 Earnings Preview
McKesson (NYSE: MCK ) unveils its next round of earnings this Thursday, Oct. 25. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement Earnings and Revenue Analysts expect McKesson ...
- Zacks•20 days ago
Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
- Zacks•25 days ago
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
- Yahoo Finance•28 days ago
Remembering Microsoft co-founder Paul Allen, dead at 65
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
Associated Press•29 days agoSalesforce vs. Twitter in San Francisco homeless tax fight
SAN FRANCISCO (AP) — San Francisco has come to be known around the world as a place for aggressive panhandling, open-air drug use and sprawling tent camps, the dirt and despair all the more remarkable for the city's immense wealth.
Market Realist•last monthAnalyzing Gilead Sciences’ Research Pipeline Developments
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
- Reuters•last month
McKesson's Change Healthcare hires IPO underwriters -sources
Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday. The move comes after McKesson Chief Executive John Hammergren said in January that he intended to take Change Healthcare public. Tapping underwriters shows that McKesson is gearing up for the IPO, which the sources said is expected to take place in the first half of 2019.
- Morningstar•2 months ago
Healthcare: Valuations Improve as Concerns Over Drug Pricing Pressures Begin to Abate
Overall, healthcare valuations have slightly risen to a price/fair value of 1.07, up from 0.98 at the end of the second quarter and 1.04 at the start of the year, but the differences in industry valuations continue to suggest drug, biotech, and drug supply chain industries are the most undervalued areas. Innovative new drug launches combined with strong advancements in drug pipelines are supporting a steady growth outlook for the drug and biotech industries. Concerns around U.S. governmental reforms addressing drug pricing appear to be easing on the valuations for drug manufacturers with the majority of reform concerns still surrounding potential changes to the drug supply chain.
Market Realist•2 months agoAnalyzing Henry Schein’s Valuation Trend
Henry Schein (HSIC) generated revenues of $3.33 billion in the second quarter, compared to revenues of $3.06 billion in the second quarter of 2017. For fiscal 2018 and 2019, the company is expected to generate revenues of $13.41 billion and $14.05 billion, respectively, compared with revenues of $12.46 billion in fiscal 2017.
Markit•2 months agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
- Simply Wall St.•2 months ago
McKesson Corporation (NYSE:MCK): Time For A Financial Health Check
Investors pursuing a solid, dependable stock investment can often be led to McKesson Corporation (NYSE:MCK), a large-cap worth US$26.33b. Market participants who are conscious of risk tend to search forRead More...
- Yahoo Finance Video•28 days ago
Drug commercials you see on TV may be overhauled
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.
